Gennady Poda
Gennady Poda
PhD, Scientific Advisor & Group Leader, Computational Chemistry and Chemoinformatics, OICR
Verified email at oicr.on.ca
Title
Cited by
Cited by
Year
Calculation of molecular lipophilicity: State-of-the-art and comparison of log P methods on more than 96,000 compounds
R Mannhold, GI Poda, C Ostermann, IV Tetko
Journal of pharmaceutical sciences 98 (3), 861-893, 2009
4642009
Can we estimate the accuracy of ADME–Tox predictions?
IV Tetko, P Bruneau, HW Mewes, DC Rohrer, GI Poda
Drug discovery today 11 (15-16), 700-707, 2006
2542006
Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2)
DR Anderson, MJ Meyers, WF Vernier, MW Mahoney, RG Kurumbail, ...
Journal of medicinal chemistry 50 (11), 2647-2654, 2007
1642007
Unleashing the therapeutic potential of human kallikrein-related serine proteases
I Prassas, A Eissa, G Poda, EP Diamandis
Nature reviews Drug discovery 14 (3), 183-202, 2015
1512015
Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia
F Grebien, M Vedadi, M Getlik, R Giambruno, A Grover, R Avellino, ...
Nature chemical biology 11 (8), 571-578, 2015
1322015
ToxAlerts: a web server of structural alerts for toxic chemicals and compounds with potential adverse reactions
I Sushko, E Salmina, VA Potemkin, G Poda, IV Tetko
Journal of chemical information and modeling 52 (8), 2310-2316, 2012
1222012
Applications of neural networks in structure-activity relationships of a small number of molecules
IV Tetko, AI Luik, GI Poda
Journal of medicinal chemistry 36 (7), 811-814, 1993
1201993
Application of ALOGPS 2.1 to predict log D distribution coefficient for Pfizer proprietary compounds
IV Tetko, GI Poda
Journal of medicinal chemistry 47 (23), 5601-5604, 2004
1162004
Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5
G Senisterra, H Wu, A Allali-Hassani, GA Wasney, D Barsyte-Lovejoy, ...
Biochemical Journal 449 (1), 151-159, 2013
962013
Molecular modelling of the ORL1 receptor and its complex with nociceptin.
CM Topham, L Moulédous, G Poda, B Maigret, JC Meunier
Protein engineering 11 (12), 1163-1179, 1998
891998
Structure and mechanism of action of the hydroxy–aryl–aldehyde class of IRE1 endoribonuclease inhibitors
M Sanches, NM Duffy, M Talukdar, N Thevakumaran, D Chiovitti, ...
Nature communications 5 (1), 1-16, 2014
742014
An Allosteric Inhibitor of Protein Arginine Methyltransferase 3
A Siarheyeva, G Senisterra, A Allali-Hassani, A Dong, E Dobrovetsky, ...
Structure, 2012
662012
HIV-1 reverse transcriptase inhibitor design using artificial neural networks
IV Tetko, VY Tanchuk, NP Chentsova, SV Antonenko, GI Poda, VP Kukhar, ...
Journal of medicinal chemistry 37 (16), 2520-2526, 1994
541994
Reconstitution and characterization of eukaryotic N6-threonylcarbamoylation of tRNA using a minimal enzyme system
LCK Wan, DYL Mao, D Neculai, J Strecker, D Chiovitti, I Kurinov, G Poda, ...
Nucleic acids research 41 (12), 6332-6346, 2013
472013
Benzothiophene inhibitors of MK2. Part 2: Improvements in kinase selectivity and cell potency
DR Anderson, MJ Meyers, RG Kurumbail, N Caspers, GI Poda, SA Long, ...
Bioorganic & medicinal chemistry letters 19 (16), 4882-4884, 2009
462009
Benzothiophene inhibitors of MK2. Part 1: Structure–activity relationships, assessments of selectivity and cellular potency
DR Anderson, MJ Meyers, RG Kurumbail, N Caspers, GI Poda, SA Long, ...
Bioorganic & medicinal chemistry letters 19 (16), 4878-4881, 2009
432009
Construction of Boron-Containing Aromatic Heterocycles
B Su, R Kinjo
Synthesis 49 (14), 2985-3034, 2017
402017
Condensation-driven assembly of boron-containing bis (heteroaryl) motifs using a linchpin approach
S Adachi, SK Liew, CF Lee, A Lough, Z He, JDS Denis, G Poda, AK Yudin
Organic letters 17 (22), 5594-5597, 2015
392015
Large‐Scale Evaluation of log P Predictors: Local Corrections May Compensate Insufficient Accuracy and Need of Experimentally Testing Every Other Compound
IV Tetko, GI Poda, C Ostermann, R Mannhold
Chemistry & Biodiversity 6 (11), 1837-1844, 2009
382009
Structure-based optimization of a small molecule antagonist of the interaction between WD repeat-containing protein 5 (WDR5) and mixed-lineage leukemia 1 (MLL1)
M Getlik, D Smil, C Zepeda-Velázquez, Y Bolshan, G Poda, H Wu, A Dong, ...
Journal of medicinal chemistry 59 (6), 2478-2496, 2016
362016
The system can't perform the operation now. Try again later.
Articles 1–20